Global Dry Powder Inhaler Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Dry Powder Inhaler market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Dry Powder Inhaler market."
A dry-powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus. DPIs are an alternative to the aerosol-based inhalers commonly called metered-dose inhaler (or MDI).
Chronic obstructive pulmonary disease will continue to be the fast-expanding application of dry powder inhalers.

The global Dry Powder Inhaler market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Dry Powder Inhaler volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dry Powder Inhaler market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Astrazeneca
    3M
    GlaxoSmithKline
    Novartis
    Cipla
    Teva
    Boehringer Ingelheim
    Chiesi Farmaceutici
    MannKind
    Vectura

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Single Dose Dry Powder Inhaler
    Multi Dose Dry Powder Inhaler

Segment by Application
    Asthma
    Chronic Obstructive Pulmonary Disease
    Pulmonary Arterial Hypertension
    Others